# I-SPY (NCT01042379)

> I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01042379
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: QuantumLeap Healthcare Collaborative
- Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer
- Interventions: Standard Therapy; AMG 386 with or without Trastuzumab; AMG 479 (Ganitumab) plus Metformin; MK-2206 with or without Trastuzumab; AMG 386 and Trastuzumab; T-DM1 and Pertuzumab; Pertuzumab and Trastuzumab; Ganetespib; ABT-888; Neratinib; PLX3397; Pembrolizumab - 4 cycle; Talazoparib plus Irinotecan; Patritumab and Trastuzumab; Pembrolizumab - 8 cycle; SGN-LIV1A; Durvalumab plus Olaparib; SD-101 + Pembrolizumab; Tucatinib plus trastuzumab and pertuzumab; Cemiplimab; Cemiplimab plus REGN3767; Trilaciclib with or without trastuzumab + pertuzumab; SYD985 ([vic-]trastuzumab duocarmazine); Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab; Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab; Amcenestrant; Amcenestrant + Abemaciclib; Amcenestrant + Letrozole; ARX788; ARX788 + Cemiplimab; VV1 + Cemiplimab; Datopotamab deruxtecan; Datopotamab deruxtecan + Durvalumab; Zanidatamab; Lasofoxifene; Z-endoxifen; ARV-471; ARV-471 + Letrozole; ARV-471 + Abemaciclib; Endoxifen + Abemaciclib; Rilvegostomig + TDXd; Dan222 + Niraparib; Sarilumab + Cemiplimab + Paclitaxel; GSK 5733584; GSK 5733584 + Dostarlimab; Ivonescimab (20mg/kg Q3W)
- Enrollment: 5000
- Primary outcome: Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 58
- X threads: 36
- Podcasts: 35

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=i-spy-nct01042379

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01042379", "email": "<work email>"}; the inbox owner confirms by the emailed link.